IP Library Granted Patent US 11,654,139
Granted Patent B2
US 11,654,139 · App. 17/062,973 · Granted May 23, 2023

Anti-infective methods, compositions, and devices

Inventors: Radhakrishnan Pillai (Santa Rosa, CA); Gordon Dow (Greenbrae, CA)
Assignee: Bausch Health Ireland Limited
A61K31/454A61K9/0014A61K47/06A61K47/10A61K47/12A61K47/14A61K47/18A61K47/24Y10T83/0443
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,654,139
App. No.
17/062,973
Granted
May 23, 2023
Kind
B2
Abstract

The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.

Claims (22)

1. A method for treating onychomycosis comprising:

(a) providing a container that is suitable for storing an efinaconazole formulation for pharmaceutical use that comprises an applicator that is capable of dispensing a pharmaceutically effective dose of the efinaconazole formulation and spreading an approximately uniform amount of the efinaconazole formulation to a treatment area of a toenail to be treated by manual action after loading,

(b) loading the applicator with the dose of the efinaconazole formulation, wherein the formulation comprises 10% w/w efinaconazole, alcohol, cyclomethicone, diisopropyl adipate, either or both of C12-15 alkyl lactate and isopropyl myristate, an antioxidant, butylated hydroxytoluene (BHT), and a salt of disodium edetate ethylenediaminetetraacetic acid (EDTA), and

(c) administering the dose of the efinaconazole formulation to the treatment area of the toenail to be treated by uniform manual spreading.

2. The method of claim 1 , wherein the container is a multiple use container and the method comprises repeating steps (a)-(c) of the method for the treatment area of the toenail to be treated once a day for at least 4 weeks.

3. The method of claim 1 , wherein the method comprises manually loading of the applicator with the dose of the efinaconazole formulation.

4. The method of claim 3 , wherein the container is a squeeze sensitive container and the applicator is a flow through applicator which delivers the efinaconazole formulation to the treatment area of the toenail to be treated when a user applies sufficient pressure on the container.

5. The method of claim 1 , wherein the method is performed for at least 36 weeks.

6. The method of claim 5 , wherein the method is performed for 48 weeks.

7. The method of claim 1 , wherein the applicator is selected from the group consisting of a brush, a pad, a swab, a sponge, or a roller.

8. The method of claim 1 , wherein the volume of efinaconazole formulation contained in the applicator is about 75 to about 150 microliters.

9. The method of claim 1 , wherein the method comprises cutting the toenail to be treated once every two weeks or more frequently.

10. The method of claim 1 , wherein the method does not comprise cutting the toenail to be treated more often than every two weeks.

11. The method of claim 1 , wherein the efinaconazole formulation is not administered in an occluded or semi-occluded manner.

12. The method of claim 1 , wherein the efinaconazole formulation is administered without debriding the nail or nail-associated tissue of the toenail to be treated initially or during the treatment period.

13. The method of claim 1 , wherein the efinaconazole formulation is administered without removing the formulation from the treatment area of the toenail to be treated during the treatment period.

14. The method of claim 1 , wherein the formulation further comprises water.

15. The method of claim 1 , wherein the average amount of efinaconazole delivered to each cm2 of the treatment area of the toenail to be treated is about 0.15 mg/cm2 to about 0.45 mg/cm2.

16. The method of claim 1 , wherein performance of the method in a patient population results in a mycological cure rate of at least about 40%, a clinical efficacy rate of at least about 20%, a complete cure rate of at least about 10%, or a combination of any or all thereof.

17. The method of claim 1 , wherein the efinaconazole formulation is administered to the treatment area of each toenail of a subject by uniform manual spreading.

18. The method of claim 17 , wherein the subject is a human subject.

19. The method of claim 18 , wherein the efinaconazole formulation is administered to the treatment area of each toenail of the human subject.

Assignments (12)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 9, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063942/0001 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2022
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 061662/0581 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: PILLAI, RADHAKRISHNAN; DOW, GORDON
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 053973/0592 →